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MicroparticleWepreviously showed that the phosphorylation of Ser253within the cytoplasmic domain of human tissue factor
(TF) initiates the incorporation and release of this protein into cell-derived microparticles. Furthermore, subse-
quent phosphorylation of Ser258 terminates this process. However, the identity of the kinase responsible for
the phosphorylation of Ser258 andmode of action of this enzyme remain unknown. In this study, p38αwas iden-
tiﬁed as the proline-directed kinase capable of phosphorylating Ser258 speciﬁcally, and without any detectable
activity towards Ser253. Furthermore, using synthetic peptides, it was shown that the Km for the reaction de-
creased by approximately 10 fold on substitution of Ser253 with phospho-Ser253. Either inhibition of p38
using SB202190 or knockdown of p38α expression in coronary artery endothelial cells overexpressing
wild-type TF, resulted in decreased phosphorylation of Ser258, following activation of cells with PAR2-agonist
peptide (PAR2-AP). In agreement with our previous data, inhibition of phosphorylation of this residue
maintained the release of TF. Activation of PAR2 in cells transfected to overexpress TF, resulted in two separate
peaks of p38 activity at approximately 40 and 120 min post-activation. Furthermore, overexpression of
Ala253-substituted TF enhanced the second p38 activation peak. However, the second peak was absent in cells
devoid of TF or in cells overexpressing the Asp253-substituted TF. Our data clearly identiﬁes p38α as a kinase
capable of phosphorylating Ser258 within the cytoplasmic domain of TF. Moreover, it appears that the presence
of TF within the cells regulates the late activation of p38 and consequently the termination of TF release into
microparticles.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Within the sequence of human tissue factor (TF), there are two cyto-
plasmic serine residues (Ser253 andSer258) thatmaybephosphorylated.
The phosphorylation of TF has beendemonstrated both in vitro and in vivo
and the inﬂuence of TF phosphorylation on cellular signalling [1,2], angio-
genesis [3–5], tumour development [5–8] and cell migration [9–11] has
been demonstrated. Previously, we demonstrated the regulation of the
incorporation and release of TF through the phosphorylation of Ser253
and Ser258 [12]. We showed that the phosphorylation of Ser258 within
the cytoplasmic domain of TF terminates the incorporation of TF into
microparticles. Furthermore, the phosphorylation of Ser258 is enhanced
by, and ensues the phosphorylation of Ser253 [12,13]. The phosphoryla-
tion of Ser253 is known to be mediated by protein kinase Cα [13,14]. In
contrast, the kinase capable of phosphorylating Ser258has not been iden-
tiﬁed. The primary sequence of the region encompassing this amino acid
corresponds to the consensus substrate site for proline-directed kinasesonary artery endothelial cells;
ptide)
+44 1482 465458.
rights reserved.or thenuclear protein p34cdc2 [15,16]. Furthermore, theprimary sequence
of this phosphorylation site is conserved between a number of species
[12,17]. In this study we have identiﬁed the kinase responsible for the
phosphorylation of Ser258 as p38α-MAPK and implicated this in the
termination of the release of TF into microparticles.
2. Material and methods
2.1. Cell culture, DNA transfection and microparticle isolation
The pCMV-XL5-TF plasmid for the expression of full-length human
TF was obtained from OriGene (Rockville, USA). Mutant plasmids
containing aspartate and alanine substitutions at Ser253 or Ser258
were as described before [12]. Human coronary artery endothelial
cells (HCAEC) were cultured and adapted to serum-free medium
(SFM) and used throughout as before [12,18]. These cells do not either
constitutively express TF or spontaneously release microparticles but
may be activated using PAR2-agonist peptide (PAR2-AP) to release
microparticles [12,18] and previously shown to be similar to activation
with factor Xa [12,14]. HCAEC were transfected to overexpress TF or
in some experiments were pre-incubated with TNFα (10 ng/ml) for
24 h to induce TF expression. The expression of TF was conﬁrmed by
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[12,19].2.2. Analysis of microparticle density and TF antigen and activity
Total TF antigen within each isolated sample was measured using
a TF-ELISA kit (Enzyme Research Laboratories, Swansea, UK) as de-
scribed before [12,18–21]. In some experiments, the phosphorylated
form of TF was detected using a rabbit anti-phosphoserine258-TF anti-
body (Abcam, Cambridge, UK). To conﬁrm TF release, the activities of
TF-containing and control microparticles were measured using a chro-
mogenic assay based on quantifying the activity of the generated throm-
bin and also, veriﬁed by measuring the activity in the presence of an
inhibitory anti-TF antibody, as previously described [8,19]. Microparticle
release from cells was veriﬁed as described previously [12,18,20].2.3. Western blot analysis
HCAEC were lysed in phosphosafe-lysis buffer (100 μl; Active Motif,
Rixensart, Belgium) and the concentrations of total protein and TF
antigen determined using Bradford protein-estimation assay and a
TF-speciﬁc ELISA respectively. The ratios of phosphorylated:total TF in
the cell lysates, equivalent amounts of TF protein were assessed as
previously described [12]. Brieﬂy, the phosphorylation of Ser258 in
cells was examined using a rabbit anti-phosphoserine258-TF antibody
(Abcam) speciﬁc for phospho-Ser258, diluted 1:2000 (v/v) in TBST
which was incubated for 2 h. The speciﬁcity and accuracy of the
antibody was previously determined [12]. The membranes were then
probed with a goat anti-rabbit HRP-conjugated antibody diluted
1:1000 (v/v). All visible bands were recorded using the GeneSnap Pro-
gram (SynGene, Cambridge, UK). Total TF antigen was also measured
as above and the ratios of phospho-Ser258 to total TF antigen deter-
mined using a monoclonal antibody to TF (10H10) (Santa Cruz Biotech-
nology, Heidelberg, Germany). The membranes were then washed and
probed with a goat anti-mouse alkaline phosphatase-conjugated anti-
body (Santa Cruz Technologies) diluted 1:1000 (v/v), incubated for
90 min. The TF bands were then visualised using the Western Blue
stabilised alkaline phosphatase-substrate (Promega Corp. Southamp-
ton, UK) and recorded as above. The ratio of the phosphorylated to
total TF was then determined using the GeneTool program (SynGene).
To assess the ratios of phosphorylated:total p38 or ERK1/2 in the cell
lysates, equivalent proteins quantities were analysed for phosphorylated
and total p38 and ERK1/2 using paired-antibody sets, obtained from
Cell Signalling Technology (New England Biolabs, Hitchin, UK), diluted
1:2000 (v/v) in TBST. All samples were probed with goat anti-rabbit
HRP-conjugated antibody diluted 1:1000 (v/v), developed and recorded
as above.2.4. Inhibition of p38 activity and siRNA-mediated knockdown of p38α
In some experiments, the cells were pre-incubated for 30 minwith a
range of concentrations of the p38 inhibitor SB202190 (30–100 nM) to
inhibit the activity of p38. The inhibition of p38 was conﬁrmed before-
hand by measuring the phosphorylation of ATF2 by western blot analy-
sis (Supplemental Data A). Also in some cases, the activity of Mek1 was
inhibited using PD98059 (0–50 μM) and conﬁrmed by analysing ERK1/2
phosphorylation (Supplemental Data B). To suppress the expression
of p38 HCAEC were transfected with p38α-speciﬁc siRNA or a control
siRNA (Santa Cruz Biotechnology) using Lipofectin (Life Technologies,
Paisley, UK) and the expression of p38 monitored using western blot
analysis. The optimal amount of siRNA (Supplemental Data C) and the
time-point of silencing were determined prior to analysis. In some
experiments, cells were co-transfected with pCMV-XL5-TF and p38- or
control-siRNA.2.5. Measurement of the kinase activity of p38α
The activity of recombinant p38α (50 ng/ml) and ERK (83 ng/ml)
(ProQinase GmbH, Freiburg, Germany) towards recombinant TF
(0–3 μM, American Diagnostica Inc., Stamford, USA) or synthetic
peptides (0–40 μM) was measured using the Kinase-Glo assay kit
(Promega). All protocols were according to the manufacturer's instruc-
tions and the relative light units (RLU) measurements were converted
to concentrations of ADP generated according to the standard curve de-
scribed in the kit. Brieﬂy, the following reagents were assembled at the
ﬁnal dilutions shown. p38 enzyme (50 ng/ml) was reconstituted in
the kinase buffer (50 mM HEPES-NaOH pH 7.5, PEG2000 (0.25 mg/ml),
1 mM DTT). The substrates, recombinant full-length TF (0–3 μM), or
synthetic cytoplasmic domain peptides (0–40 μM), were reconstituted
in HEPES buffer-NaOHpH 7.5 (50 mM) beforehand. The assay buffer re-
agentwas assembled to a volume of 10 μl, containingHEPES-NaOHbuffer
pH 7.5 (50 mM), MgCl2 (3 mM), MnCl2 (3 mM), Na-orthovanadate
(3 μM), DTT (1 mM) and DMSO (1% w/v). 5 μl of ultrapure ATP
(10 mM), 5 μl of enzyme and 5 μl of the substrate were added and
incubated at 30 °C for 40 min. The reaction was then stopped by
adding the ADP-Glo reagent (25 μl) and incubated for 40 min. Finally,
the Kinase-Detection reagent (50 μl) was added, incubated at room
temperature for 60 min and the relative light units (RLU) recorded
using a luminometer (Berthold Technologies GmbH & Co., Bad Wildbad,
Germany). The assays were carried out at the substrate concentrations
stated above and the Km and Vmax valueswere then calculated. Peptides
corresponding to the last 18-amino acids within the cytoplasmic domain
of TF were synthesised as wild-type, or with alanine, aspartate or
phospho-serine substitutions in either of the two serine residues corre-
sponding to residues 253 and 258 (underlined), as described before
[12,22]. The sequences of the synthetic peptides were as shown below.
Ser253/Ser258: RKAGVGQSKENWSPLNVS,
Ala253/Ser258: RKAGVGQAKENWSPLNVS,
Asp253/Ser258: RKAGVGQDKENWSPLNVS,
Ser253/Ala258: RKAGVGQSKENWAPLNVS,
pSer253/Ser258: RKAGVGQpSKENWSPLNVS,
scrambled: KGSAKESNGPWSNVLQRV.
2.6. Statistical analysis
All data represent the calculated mean values from the number of
experiments stated in each ﬁgure legend±the calculated standard
error of the mean. Statistical analysis was carried out using the Statisti-
cal Package for the Social Sciences (SPSS Inc. Chicago, USA). One-Way
ANOVA procedure was used for the analysis of variance of data against
the control with Tukey's honestly signiﬁcant difference test to highlight
statistically signiﬁcant differences.
3. Results
Transfection efﬁciencies, TF protein expression and cell viability
values were as previously determined and reported [12]. The effective-
ness of SB202190 to inhibit p38 activity was conﬁrmed by measuring
the phosphorylation of ATF2 by western blot analysis (Supplemental
Data A). In addition, the activity of Mek1 was inhibited using PD98059
(0–50 μM) and conﬁrmed by analysing ERK1/2 phosphorylation
(Supplemental Data B). Transfection efﬁciency of the siRNA, determined
using FITC-labelled siRNA, was more than 80% and the optimal concen-
tration of siRNA for p38α knockdown was determined to be 0.46 μg
(Supplemental Data C). The expression of ERK1/2 and the housekeeping
gene GAPDH remained unaltered by either siRNA transfection (Supple-
mental Data C and D). Additionally, no alteration in cell numbers
subsequent to transfection of siRNA or overexpression of TF was
observed (not shown). Finally, we have previously demonstrated the
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rations of HCAEC-derived microparticles [18].3.1. Time-course of p38 and ERK1/2 phosphorylation in TF-overexpressing
cells following PAR2 activation
Stimulation of HCAEC overexpressing TFWt with PAR2-AP (20 μM)
induced the transient phosphorylation of p38 which peaked at two
distinct time-points of 40 and 120 min post-activation (Fig. 1A). The
earlier peak was concurrent with the phosphorylation of ERK1/2
(Fig. 1B). In contrast, only the earlier p38 peak, together with the activa-
tion of ERK1/2, was detected in cells devoid of TF. Overexpression of the
TFmutant with Ala-substitution of residue 253 (TFAla253) resulted in the
augmentation of the second p38 peak at 120 min (Fig. 1C) without
affecting the earlier p38 peak (Fig. 1D) or ERK1/2 activity (not shown).
The proﬁles of p38 activation (Fig. 1C and D) and ERK1/2 (not shown)
phosphorylations, in HCAEC overexpressing Asp253-substituted TF
(TFAsp253), exhibited a pattern similar to untransfected cells. Finally,0
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HCAEC were transfected to overexpress TFWt and the cells were
incubated with a range of concentrations of SB202190 to inhibit p38
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pression of Ser258 phosphorylation was not achieved (Fig. 2D).3.3. p38 phosphorylates recombinant TF in vitro
To conﬁrm the ability of p38 to phosphorylate TF in vitro, an attempt
was made to analyse the phosphorylation of non-phosphorylated
recombinant full-length TF (0–3 μM) in a luminescence-based kinase
assay employing a recombinant-active p38α protein (50 ng/ml). The
Km value for the reaction was calculated to be 1.74±0.25 μM and the
Vmax for the reaction was 12.8±1.5 nmol/s/mg enzyme and the calcu-
lated Kcat value was 256 s−1 (Table 1). The calculated p38α Vmax
value, with non-phosphorylated full-length TF as substrate was similar
to that provided by the supplier (ProQinase) for the p38-substrate
ATF2 (14.9 nmol/s/mg) and the Km value is in line with published
value [23]. To conﬁrm the phosphorylation of the recombinant TF
(1.5 μM), the reaction was also carried out in the presence and
absence of ATP and phosphorylation state of TF determined by
western blot and ELISA analysis, probed with a rabbit
anti-phosphoserine258-TF antibody. The product from the reaction
containing ATP, but not from the reaction devoid of ATP was
recognised by the anti-phospho-TF antibody when examined by
western blot or by ELISA (Fig. 3) and conﬁrming the phosphoryla-
tion of TF. In addition, conducting the kinase assay using ERK in-
stead of p38 resulted in minimal phosphorylation of TF but only at
high concentrations of the substrate protein.3.4. Demonstration of the speciﬁcity of p38α activity towards Ser258
within TF
In order to demonstrate that p38 speciﬁcally phosphorylated Ser258
within TF, a number of peptides corresponding to the last 18 amino
acids of the cytoplasmic domain of human TF were synthesised and
tested using the p38α kinase assay. The peptides included the wild-
type or containing alanine substitutions in the positions corresponding
to residues 253 and 258. Signiﬁcant p38 kinase activity was detected
towards all of the peptides that contained serine at position 258
(Fig. 4) while no measurable activity was detectable when this residue
was substituted with alanine or when using a scrambled peptide.
3.5. Phosphorylation of Ser253 enhances the phosphorylation of Ser258
by p38
In order to assess the impact of the phosphorylation state of Ser253,
on the p38 kinase activity towards Ser258, a set of peptides, each 18
amino acids long were prepared, but containing serine, alanine, aspar-
tate and phospho-serine residues at position corresponding to Ser253
and the kinase activity of p38α assessed. The data show that either
aspartate or phospho-serine substitution at Ser253 enhanced the rate
of p38α activity towards Ser258, compared to peptides containing
serine or alanine at the position corresponding to Ser253 (Fig. 4). The
enhanced rate of reaction for p38α was reﬂected in lower Km values in
the presence of aspartate or phospho-serine at position 253 and indicates
a higher afﬁnity of p38α (up to 10-fold) for the Ser253-phosphorylated
Table 1
Calculated kinetics values for the activity of p38α. The activity of recombinant p38α
(50 ng/ml) towards recombinant TF (0–3 μM) or synthetic peptides (0–40 μM) corre-
sponding to the last 18-amino acids within the cytoplasmic domain of TF was measured
using the Kinase-Glo assay kit and the relative light units (RLU) measurements converted
to concentrations of ADP generated according to the standard curve described in the kit.
The Km and Vmax values were then calculated.
Substrate
designation
Sequence Km (μM) Vmax
(nmol/s/mg)
SS RKAGVGQSKENWSPLNVS 2.21±0.35 10.0±0.7
DS RKAGVGQDKENWSPLNVS 0.78±0.23 13.3±1.8
pSS RKAGVGQpSKENWSPLNVS 0.22±0.09 10.2±1.1
- Recombinant TF protein
(unphosphorylated)
1.74±0.25 12.8±1.5
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did not alter signiﬁcantly indicating no change in the enzyme activity
of p38α.
3.6. The inﬂuence of p38 inhibition/suppression on TF release as
microparticles, following PAR2 activation
HCAEC were transfected to overexpress TFWt and the cells were
incubated with a range of concentrations of SB202190 to inhibit p38,
or PD98059 to prevent the activation of ERK1/2 byMek1, prior to activa-
tion of PAR2. In agreement with our previous data [12], stimulation of
HCAEC overexpressing TFWt with PAR2-AP (20 μM) resulted in the
transient incorporation and release of TF antigen into microparticles at
90 min but declined by 120 min (Fig. 5A). However, we have previously
shown that the microparticles are readily taken up by endothelial cells
in culture [12,18]. Therefore, the observed changes in TF concentrations
in the media represent the net ﬂux of the TF within the released0
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or absence of ATP. Similar kinase assays were also performed in the presence of recombinant
western blot analysis using an anti-phosphoserine258-TF antibody (Representative of 3 separ
ELISA. Following the kinase reaction, TF was captured using anti-TF antibody and probed for umicroparticles. In agreement with our previous data, at the point of
maximal release, the relative amount of cellular TF was marginally
less in the cells overexpressing Asp253-substituted TF compared to
wild-type TF, and was higher in the sample overexpressing Ala253-
substitued TF (Fig. 5B). In addition, no TF release was observed in either
untransfected PAR2-AP activated cells, or in cells that overexpressed TF
but were incubated with a scrambled PAR2-AP peptide (Fig. 5A).
Pre-incubation of cells with SB202190 marginally reduced the release
of TF at 90 min (Fig. 5C) which could be explained by a modest reduc-
tion inmicroparticle density (Fig. 5D) and is in agreementwith previous
reports [24]. In contrast, the level of released TF was increased at
120 min (Fig. 5C). A greater alteration in the level of the incorporation
of TF into microparticles was also achieved on suppression of p38
expression in cells, with a p38-speciﬁc siRNA but not with the control
siRNA (Fig. 5E) while the alteration in microparticle density was not
signiﬁcant (Fig. 5D). Incubation of cells with higher concentrations of
PD98059 marginally increased the level of TF released at 90 min
(Fig. 5F) but not 120 min (not shown).
4. Discussion
We previously demonstrated the regulation of the incorporation of
TF into cell-derived microparticles through the phosphorylation of the
cytoplasmic domain of this protein [12]. In this study, the ability TF to
induce p38 MAPK pathway activation was demonstrated (Fig. 1). The
induction of p38 MAPK signalling following the activation of PAR2 has
been established [11]. However, unlike the initial p38 activation peak,
initiated by PAR2 and observed at 40 min, the TF-mediated induction
of p38 activity, observed at 120 min was distinct from that initiated
by PAR2 alone. This ability arose from the presence of TF within the
cells, following activation of PAR2. The direct induction of p38 activa-
tion by TF has been suggested [11] but a mechanism not demonstratedERK kinase
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Fig. 4. p38α phosphorylates recombinant TF in vitro. Peptides corresponding to the C-terminal 18 amino acids of wild-type TF, and alanine, aspartate and phospho-serine substitutions at
positions corresponding to Ser253 or Ser258were incubated with recombinant p38α, and p38 kinase activity monitored using a luminescence-based kinase assay. (n=7, *=pb0.05 vs.
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tion of TF release through alanine-substitution of residue 253 enhanced
the second phase of p38 activity while acceleration of TF release
through aspartate–substitution eliminated this peak (Fig. 1C and D).
In addition, alanine mutation of Ser258 had no bearing on p38 activa-
tion and therefore indicates that the activation of p38 precedes, and is
not inﬂuenced by the phosphorylation of Ser258. Therefore we
hypothesise that the second wave of activation of p38 is dependent
on the presence of TF protein itself, but subsequent to induction of
PAR2. This ﬁts well with our previous report suggesting that the phos-
phorylation of Ser258 within human TF is regulated by both TF itself
and requires the activation of PAR2 [12]. In addition, it has been
shown that the de-palmitoylation of Cys245 is a precursor event to
the tandem phosphorylation of the two serine residues [13,15,25].
This event may in effect permit the relocation of TF out of cellular re-
gions, or the mobilisation of TF to speciﬁc membrane regions, exposing
the cytoplasmic domain to target kinases. Prolonged activation of p38
pathway is thought to be the hallmark of induction of p38-mediated
cell apoptosis, while short durations of activity appear to coincide
with cell proliferation [26]. Furthermore, the increase in ERK activity co-
incided with the ﬁrst p38 activity peak and preceded the release of TF
into microparticles. Therefore, it may be suggested that the release of
TF in effect has an anti-inﬂammatory/anti-apoptotic inﬂuence on the
parent cell, and is mediated through transient phosphorylation of
both ERK and p38 pathways. In contrast, it appears that the persistence
of TF in cells, following activation, promotes the prolonged activation of
p38 which may lead to inﬂammatory responses and apoptosis [26]. In
this study, a model of PAR2-activated endothelial cells, in which TF
was overexpressed,was used. Thismodel permits the systematic exam-
ination of the regulation of the phosphorylation and release of TF,
without any interference fromother inﬂammatory signals. It also allows
the study of mutant forms of TF with minimal interference from
the wild-type cellular TF. In addition, parallel sets of cells were
pre-incubatedwith TNFα to express the cellular TF. However, the phys-
iological outcomes of these events must also include cellular signals
arising from other inﬂammatory mediators.
The phosphorylation of both p38 and ERK preceded the phosphory-
lation of Ser258 within TF. Furthermore, both of these proteins may act
as proline-directed kinases. Therefore, the possibility that p38 and ERK
may be responsible for the phosphorylation of Ser258 within TF was
explored. Inhibition of p38 activity using SB202190, prior to activation
with PAR2-AP, resulted in reduced phosphorylation of Ser258 within
TF (Fig. 2A and B). Moreover, this was concurrent with the maintainedlevel of release of TF within microparticles, at 120 min (Fig. 5C). This is
in agreement with our previous data showing that mutation of Ser258
to alanine prevents the curtailment of the release of TF at 120 min,
while aspartate-substitution of this residue suppresses the release of
TF [12]. Therefore, if p38 was not responsible for the phosphoryaltion
of Ser258 within TF, in the presence of p38 inhibitor/siRNA, less total
TF ought to be present within the cells and consequently, the ratio of
phosphosereine-258-TF/Total TF should be higher than that without
the inhibitor/siRNA. However, asmay be seen in Fig. 2, this ratio actually
dropped as a consequence of p38 inhibition/suppression. Therefore, it
may be suggested that once sufﬁcient amounts of TF are released, the
process is self-regulated by amechanismwhich is itself activated during
TF release phase. Interestingly, at a concentration of 30 nM, SB202190
signiﬁcantly inhibited the phosphorylation of TF by p38. This suggests
the involvement of p38α, since p38β activity is not affected by this
concentration of SB202190 [27]. Furthermore, knockdown of p38α
expression using a speciﬁc siRNA, suppressed the phosphorylation
of Ser258 within TF at 120 min (Fig. 2C and D) while concurrently
prolonging the release of TF at 120 min (Fig. 5D). However, although
the phosphorylation of Ser258 was largely inhibited, complete suppres-
sion was not achieved. Moreover, low levels of phosphorylation of TF
was only achievable using ERK, when using high concentrations of TF
(Fig. 3). Consequently, the possibility that other kinases such as ERK
may also be capable of phosphorylation, TF under different cellular con-
ditions, cannot be ruled out. In summary, these data support the ability
of p38α as the major kinase, responsible for the phosphorylation of
Ser258 within TF.
The ability of p38α to phosphorylate Ser258 within TF was con-
ﬁrmed using a luminescence-based kinase assay containing active
recombinant p38α. In addition, the product from the reaction, but not
from a negative reaction control devoid of ATP, was recognised by a
speciﬁc antibody against phosphoserine258, within TF (Fig. 3). From
the data using peptides corresponding to the cytoplasmic domain of
TF (Fig. 4), it may be concluded that the serine residue at position 258
acts as a substrate for p38α. Furthermore, Ser253 does not constitute
a viable phosphorylation site for this kinase. Moreover, the phosphory-
lation of the serine at the position corresponding to residue 258, by
p38α, was substantially enhanced by the presence of either aspartate
or phospho-serine at the position corresponding to residue 253 (Fig. 4
and Table 1). Therefore, we suggest that the observed reduction of the
Km value for the phosphorylation of Ser258 by p38α, following phos-
phorylation of Ser253 (Table 1) may also arise from the steric exposure
of Ser258. It is however important to note the Km value for the
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619C. Ettelaie et al. / Biochimica et Biophysica Acta 1833 (2013) 613–621full-length TF may also be subject to the positioning of this protein
within the cell membrane.
By comparing theNMR-basedmolecular structures of the cytoplasmic
domain of TF, Sen, et. al. [17] suggested that the reduction in the overall
positive charge of the peptide may be sufﬁcient to permit the activity
of suitable kinase towards Ser258. We have further examined these
published structures which also indicate that in the unphosphorylatedpeptide, Lys255 may be interacting with Ser258 preventing any further
interactions (Fig. 6A). The phosphorylation of Ser253 results in the alter-
ation of the φ and ψ torsional angles within Trp254 and Lys255 from
extended conﬁguration to almost a loop (Fig. 6B). This in turn appears
to reposition both Lys255 and Trp254 away from Ser258, opening a
pocket to permit access to Ser258 (Fig. 6A). In addition, examination of
the variations in the top ten structures of these peptides [17] suggest
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Fig. 6. Proposed molecular mechanism for the induction of Ser258 phosphorylation by p38. The structure of the cytoplasmic domain of TF in the unphosphorylated (2CEH) (left)
and phospho-Ser253 (2CEZ) (right) forms (17) were edited to retain the residues 253–263 and (A) then viewed using the Raswin program (version 2.7.5). (B) The sequence of
amino acids between residues 253–259 were uploaded onto the Alchemy III program and coloured to highlight the backbone structure.
620 C. Ettelaie et al. / Biochimica et Biophysica Acta 1833 (2013) 613–621that the phosphorylation of Ser253 results in greatly reducedﬂexibility of
Lys255 and Trp254 (not shown) and therefore reduced ability of these
two amino acids to interferewith the exposed Ser258. Therefore, we sug-
gest that the observed reduction of the Km value for the phosphorylation
of Ser258 by p38α, following phosphorylation of Ser253 (Table 1) may
also arise from the steric exposure of Ser258.
5. Conclusions
We previously showed an association between the phosphorylation
of Ser258 and the termination of TF release within cell-derived micro-
particles [12]. Our current study has identiﬁed p38α as a major kinase,
responsible for the phosphorylation of Ser258 within the cytoplasmic
domain of TF. Furthermore, the phosphorylation of Ser253 within
the cytoplasmic domain of TF increases the afﬁnity of p38α for TF
and accelerates the rate of phosphorylation of Ser258. Moreover, the
phosphorylation of Ser258 is concurrent with a second activation
phase of p38 which itself, appears to depend on the presence of TF in
the activated cells. Such a mechanism may constitute a means of
monitoring of the amount of TF incorporated into microparticles by
the cell, and therefore may also be a means of regulation of the level
of cellular TF.Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2012.11.010.
References
[1] L.V. Rao, U.R. Pendurthi, Tissue factor-factor VIIa signaling, Arterioscler. Thromb.
Vasc. Biol. 25 (2005) 47–56.
[2] J. Ahamed, F. Niessen, T. Kurokawa, Y.K. Lee, G. Bhattacharjee, J.H. Morrissey,W. Ruf,
Regulation of macrophage procoagulant responses by the tissue factor cytoplasmic
domain in endotoxemia, Blood 109 (2007) 5251–5259.
[3] M. Belting, M.I. Dorrell, S. Sandgren, E. Aguilar, J. Ahamed, A. Dorﬂeutner, P.
Carmeliet, B.M. Mueller, M. Friedlander, W. Ruf, Regulation of angiogenesis by
tissue factor cytoplasmic domain signalling, Nat. Med. 10 (2004) 502–509.
[4] C. López-Pedrera, N. Barbarroja, G. Dorado, E. Siendones, F. Velasco, Tissue factor as
an effector of angiogenesis and tumor progression in hematological malignancies,
Leukaemia 20 (2006) 1331–1334.
[5] W. Ruf, N. Yokota, F. Schaffner, Tissue factor in cancer progression and angiogenesis,
Thromb. Res. 125S2 (2010) S36–38.
[6] F. Schaffner, H.H. Versteeg, A. Schillert, N. Yokota, L.C. Petersen, B.M. Mueller, W.
Ruf, Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast
cancer development, Blood 116 (2010) 6106–6113.
[7] L. Rydén, D. Grabau, F. Schaffner, P.E. Jönsson, W. Ruf, M. Belting, Evidence for tissue
factor phosphorylation and its correlation with protease-activated receptor expression
and the prognosis of primary breast cancer, Int. J. Cancer 126 (2010) 2330–2340.
[8] C. Li, M.E. Collier, G.A. Frentzou, J. Greenman, C. Ettelaie, Investigation of the
mechanisms of tissue factor-mediated evasion of tumour cells from cellular
cytotoxicity, Cancer Immunol. Immunother. 57 (2008) 1347–1355.
621C. Ettelaie et al. / Biochimica et Biophysica Acta 1833 (2013) 613–621[9] A. Dorﬂeutner, E. Hintermann, T. Tarui, Y. Takada, W. Ruf, Cross-talk of integrin
alpha3beta1 and tissue factor in cell migration, Mol. Biol. Cell 15 (2004) 4416–4425.
[10] A. Siegbahn, M. Johnell, B.B. Sorensen, L.C. Petersen, C.H. Heldin, Regulation of chemo-
taxis by the cytoplasmic domain of tissue factor, Thromb. Haemost. 93 (2005) 27–34.
[11] I. Ott, B. Weigand, R. Michl, I. Seitz, N. Sabbari-Erfani, F.J. Neumann, A. Schömig, Tissue
factor cytoplasmic domain stimulates migration by activation of the GTPase Rac1 and
the mitogen-activated protein kinase p38, Circulation 111 (2005) 349–355.
[12] M.E. Collier, C. Ettelaie, Regulation of the incorporation of tissue factor into
microparticles by serine phosphorylation of the cytoplasmic domain of tissue
factor, J. Biol. Chem. 286 (2011) 11977–11984.
[13] A. Dorﬂeutner,W. Ruf, Regulation of tissue factor cytoplasmic domain phosphorylation
by palmitoylation, Blood 102 (2003) 3998–4005.
[14] J. Ahamed, W. Ruf, Protease-activated receptor 2-dependent phosphorylation of
the tissue factor cytoplasmic domain, J. Biol. Chem. 279 (2004) 23038–23044.
[15] T.F. Zioncheck, S. Roy, G.A. Vehar, The cytoplasmic domain of tissue factor is
phosphorylated by a protein kinase C-dependent mechanism J, Biol. Chem. 267
(1992) 3561–3564.
[16] R.S. Mody, S.D. Carson, Tissue factor cytoplasmic domain peptide is multiply
phosphorylated in vitro, Biochemistry 36 (1997) 7869–7875.
[17] M. Sen, M. Herzik, J.W. Craft, A.L. Creath, S. Agrawal, W. Ruf, G.B. Legge, Spectroscopic
Characterization of Successive Phosphorylation of the Tissue Factor Cytoplasmic
Region, Open Spectrosc. J. 3 (2009) 58–64.
[18] M.E. Collier, C. Ettelaie, Induction of endothelial cell proliferation by recombinant and
microparticle-tissue factor involves beta1-integrin and extracellular signal regulated
kinase activation, Arterioscler. Thromb. Vasc. Biol. 30 (2010) 1810–1817.
[19] C. Ettelaie, D. Fountain,M.E. Collier, A.M. Elkeeb, Y.P. Xiao, A.Maraveyas, Lowmolecular
weight heparin downregulates tissue factor expression and activity by modulatinggrowth factor receptor-mediated induction of nuclear factor-κB, Biochim. Biophys.
Acta 1812 (2012) 1591–1600.
[20] C. Ettelaie, M.E.W. Collier, M.P. Mei, Y.P. Xia, A.M. Maraveyas, Enhanced
binding of tissue factor-microparticles to collagen-IV and ﬁbronectin
leads to increased tissue factor activity in vitro. Thromb. Haemostas. 109
(1) (in press).
[21] C. Ettelaie, N.J. James, B. Wilbourn, J.M. Adam, K.M. Naseem, K.R. Bruckdorfer,
The mechanism of inhibition of factor III (thromboplastin) activity by
apolipoprotein B-100. Protein-protein interactions, Arterioscler. Thromb.
Vasc. Biol. 16 (1996) 639–647.
[22] C. Ettelaie, J.M. Adam, N.J. James, A.O. Oke, J.A. Harrison, T.D. Bunce, K.R.
Bruckdorfer, The role of the C-terminal domain in the inhibitory functions of
tissue factor pathway inhibitor, FEBS Lett. 463 (1999) 341–344.
[23] Y.Y. Zhang, Z.Q.Mei, J.W.Wu, Z.X.Wang, Enzymatic activity and substrate speciﬁcity
of mitogen-activated protein kinase p38alpha in different phosphorylation states,
J. Biol. Chem. 283 (39) (2008) 26591–26601.
[24] A.M. Curtis, P.F.Wilkinson,M. Cui, T.L. Gales, E.Hu, J.M. Edelberg, p38mitogen-activated
protein kinase targets the production of proinﬂammatory endothelial microparticles,
J. Thromb. Haemost. 7 (2009) 701–709.
[25] R. Bach, W.H. Konigsberg, Y. Nemerson, Human tissue factor contains thioester-linked
palmitate and stearate on the cytoplasmic half-cystine, Biochemistry 27 (1988)
4227–4231.
[26] I. Dolado, A.R. Nebreda, Regulation of Tumorigenesis by p38αMAPKinase, Top. Curr.
Genet. 20 (2008) 99–128.
[27] S.P. Davies, H. Reddy, M. Caivano, P. Cohen, Speciﬁcity andmechanism of action
of some commonly used protein kinase inhibitors, Biochem. J. 351 (2000)
95–105.
